{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:28:13Z","timestamp":1760142493815,"version":"build-2065373602"},"reference-count":146,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Adult patients affected by acute myeloid leukemia who fail to achieve remission after two cycles of intensive chemotherapy based on a combination of anthracyclines and cytarabine are considered chemorefractory and are unlikely to benefit from further induction attempts. Characterized by a poor prognosis, they may still benefit from allogeneic hematopoietic stem cell transplantation, even if long-term survival rarely exceeds 20\u201330%. Still, the use of sequential high-dose chemotherapy followed by reduced-intensity conditioning, with transplantation performed during aplasia, and the optimization of the alloreactivity of donor leukocytes against leukemia (i.e., the graft-versus-leukemia effect) may ameliorate these results. Optimization of alloreactivity against leukemic cells can be achieved by proper donor selection, by the early withdrawal of immunosuppressive therapy, by post-transplant administration of donor lymphocyte infusions as prophylaxis of leukemia relapse, and by several other maintenance and preemptive therapies. Far from being the final stage of consolidation therapy, allogeneic hematopoietic stem cell transplantation is now considered as the moment when a unique immunological platform can be established in these patients, to be used for additional post-transplant measures. In this study we will critically review the different pre- and post-transplant strategies used in clinical trials to improve long-term survival in adult patients transplanted with chemorefractory leukemia.<\/jats:p>","DOI":"10.3390\/cancers17203285","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:45:01Z","timestamp":1760089501000},"page":"3285","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic Hematopoietic Stem Cell Transplantation as a Platform to Treat Chemorefractory Acute Myeloid Leukemia in Adult Patients"],"prefix":"10.3390","volume":"17","author":[{"given":"Daniel","family":"Alzetta","sequence":"first","affiliation":[{"name":"Hematology and BMTU, Hospital of Bolzano (SABES\u2013ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), Via Lorenz Bohler 5, 39100 Bolzano, BZ, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene M.","family":"Cavattoni","sequence":"additional","affiliation":[{"name":"Hematology and BMTU, Hospital of Bolzano (SABES\u2013ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), Via Lorenz Bohler 5, 39100 Bolzano, BZ, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-369X","authenticated-orcid":false,"given":"Federico","family":"Mosna","sequence":"additional","affiliation":[{"name":"Hematology and BMTU, Hospital of Bolzano (SABES\u2013ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), Via Lorenz Bohler 5, 39100 Bolzano, BZ, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/ajh.25975","article-title":"Acute myeloid leukemia: 2021 update on risk-stratification and management","volume":"95","author":"Estey","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN Guidelines insights: Acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_4","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2011.40.5977","article-title":"Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.bmt.1702690","article-title":"Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: A retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM)","volume":"26","author":"Michallet","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/leu.2011.13","article-title":"Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia","volume":"25","author":"Craddock","year":"2011","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/ejh.12522","article-title":"Allogeneic stem cell transplantation for refractory acute myeloid leukemia: A single center analysis of long-term outcome","volume":"95","author":"Hemmati","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.leukres.2015.10.011","article-title":"Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory\/relapsed AML patients in NR status","volume":"39","author":"Liu","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3026(15)00146-5","article-title":"Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: A retrospective, multicentre, registry analysis","volume":"2","author":"Nagler","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/bmt.2016.325","article-title":"Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: A retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"52","author":"Todisco","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.30536","article-title":"Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission","volume":"123","author":"Weisdorf","year":"2017","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.26000","article-title":"The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT)","volume":"96","author":"Poiani","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1158\/1078-0432.CCR-22-0809","article-title":"Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: An ALWP\/EBMT analysis","volume":"28","author":"Nagler","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41409-022-01626-5","article-title":"Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: Final results of the GITMO prospective trial GANDALF-01","volume":"57","author":"Bonifazi","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41375-023-02119-0","article-title":"Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission","volume":"38","author":"Yanada","year":"2024","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1007\/s00277-023-05406-z","article-title":"Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: A ten-year study","volume":"102","author":"Jiang","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41409-024-02275-6","article-title":"Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"59","author":"Maffini","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcyt.2024.11.012","article-title":"Allogeneic hematopoietic stem cell transplantation using reduced intensity conditioning regimen for patients with acute myeloid leukemia not in complete remission","volume":"27","author":"Shimomura","year":"2025","journal-title":"Cytotherapy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2005-04-1377","article-title":"Cooperative German Transplant Study Group: Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia","volume":"106","author":"Stelljes","year":"2005","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1703373","article-title":"Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia","volume":"29","author":"Singhal","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.bmt.1705207","article-title":"Allogeneic stem-cell transplantation in patients with refractory acute leukemia: A long-term follow-up","volume":"37","author":"Oyekunle","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase-III study of the EBMT (RICMAC Trial)","volume":"35","author":"Kroger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: A prospective, open-label randomised phase 3 trial","volume":"13","author":"Bornhauser","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/bmt.2017.8","article-title":"Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: Potentially curative therapy","volume":"52","author":"Gyurkocza","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-013-1774-5","article-title":"Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia","volume":"92","author":"Schneidawind","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ejh.12615","article-title":"FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission","volume":"96","author":"Holtick","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00432-015-2050-y","article-title":"Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation","volume":"142","author":"Pfrepper","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/leu.2015.226","article-title":"Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: Results of the BRIDGE trial","volume":"30","author":"Middeke","year":"2016","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.bbmt.2016.07.016","article-title":"Improved outcome of refractory\/relapsed acute myeloid leukemia after post-transplantation cyclophosphamide-based haploidentical transplantation with myeloablative conditioning and early prophylactic granulocyte colony-stimulating-factor-mobilized donor lymphocyte infusions","volume":"22","author":"Jaiswal","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3324\/haematol.2016.150326","article-title":"Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia","volume":"102","author":"Mohty","year":"2017","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjh.14428","article-title":"Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: A survey from the Acute Leukaemia Working Party of EBMT","volume":"176","author":"Ringden","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bjh.14980","article-title":"Durable graft-versus-leukaemia effects without donor lymphocyte infusions- results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia","volume":"180","author":"Davies","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbmt.2018.01.005","article-title":"Sequential conditioning with thiotepa in T-cell replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: Comparison with matched related, haplo-mismatched, and unrelated donors","volume":"24","author":"Dulery","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjh.15137","article-title":"High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia","volume":"180","author":"Steckel","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e0228","DOI":"10.1097\/MD.0000000000010228","article-title":"A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-019-0727-4","article-title":"Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"12","author":"Saraceni","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","article-title":"FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in younger patients with relapsed\/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"26","author":"Labopin","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00277-020-04074-7","article-title":"Sequential allogeneic hematopoietic stem cell transplantation for active refractory\/relapsed myeloid malignancies: Results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC","volume":"99","author":"Labopin","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.4149\/neo_2021_210426N573","article-title":"A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed\/refractory acute myeloid leukemia","volume":"68","author":"Sun","year":"2021","journal-title":"Neoplasma"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2147\/CMAR.S339846","article-title":"Allogeneic stem cell transplantation with sequential melphalan-based conditioning in AML: Residual morphological blast count determines the risk of relapse","volume":"14","author":"Sockel","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41409-022-01703-9","article-title":"Long-term outcomes in patients with relapsed\/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan","volume":"57","author":"Guijarro","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/ejh.13732","article-title":"Time-dependent analysis of adoptive immunotherapy following sequential FLAMSA-reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk myeloid neoplasia","volume":"108","author":"Weller","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-023-05502-0","article-title":"CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia","volume":"103","author":"Fei","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102037","DOI":"10.1016\/j.trim.2024.102037","article-title":"Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia","volume":"84","author":"Xiao","year":"2024","journal-title":"Transpl. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.19552","article-title":"Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukemia","volume":"205","author":"Ronnacker","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ronnacker, J., Urbahn, M.-A., Reicherts, C., Call, S., Esseling, E., Floeth, M., Marx, J., Albring, J., Mikesch, J.-H., and Schliemann, C. (2025). High-dose Melphalan followed by Busulfan and Fludarabine conditioning prior to allogeneic stem cell transplantation in elderly patients with active Acute Myeloid Leukemia\u2014A retrospective single center study. Transplant. Cell. Ther., 31.","DOI":"10.1016\/j.jtct.2025.06.019"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Fraccaroli, A., Stauffer, E., Haebe, S., Prevalsek, D., Weiss, L., Dorman, K., Drolle, H., von Bergwelt-Baildon, M., Stemmler, H.-J., and Herold, T. (2024). Treosulfan-versus Melphalan-based reduced intensity conditioning in HLA-haploidentical transplantation for patients \u226550 years with advanced MDS\/AML. Cancers, 16.","DOI":"10.3390\/cancers16162859"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00277-020-04131-1","article-title":"The FLAMSA concept\u2014Past and future","volume":"99","author":"Kolb","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.bbmt.2011.09.006","article-title":"Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen","volume":"18","author":"Saure","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Jondreville, L., Roos-Weil, D., Uzunov, M., Boussen, I., Grenier, A., Norol, F., Morel, V., Nguyen, S., and Souchet, L. (2021). FLAMSA-Busulfan-Melphalan as a sequential conditioning regimen in HLA-matched or haploidentical hematopoietic stem cell transplantation for high-risk myeloid diseases. Transplant. Cell. Ther., 27.","DOI":"10.1016\/j.jtct.2021.07.018"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/bjh.19781","article-title":"Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusions for patients with relapsed\/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study","volume":"205","author":"Lv","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","article-title":"Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active","volume":"5","author":"Garcia","year":"2021","journal-title":"Blood Adv."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","article-title":"Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML","volume":"8","author":"Garcia","year":"2024","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00277-023-05226-1","article-title":"Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: A 10-year experience","volume":"102","author":"Duda","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.bbmt.2016.07.010","article-title":"Impact of donor type on outcome after allogeneic hematopoietic cell transplantation for acute leukemia","volume":"22","author":"Solomon","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bbmt.2014.10.030","article-title":"Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: Similar outcomes regardless of donor type","volume":"21","author":"Warlick","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3324\/haematol.2017.176107","article-title":"Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: A position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1600-065X.2008.00658.x","article-title":"Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells","volume":"224","author":"Joncker","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e26529","DOI":"10.4161\/onci.26529","article-title":"NK-cell fratricide: Dynamic crosstalk between NK and cancer cells","volume":"2","author":"Nakamura","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1002\/1521-4141(200111)31:11<3147::AID-IMMU3147>3.0.CO;2-F","article-title":"Critical role of NK but not NKT cells in acute rejection of parental bone marrow cells in F1 hybrid mice","volume":"31","author":"Suzue","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.coi.2009.07.015","article-title":"Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: A tool for immunotherapy of leukemia","volume":"21","author":"Velardi","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Moesta, A.K., and Parham, P. (2012). Diverse functionality among human NK ell reeptors for the C1 epitope of GLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Front. Immunol., 3.","DOI":"10.3389\/fimmu.2012.00336"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/imr.12323","article-title":"Co-evolution of NK receptors and HLA ligands in humans is driven by reproduction","volume":"267","author":"Moffett","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/sj.leu.2405040","article-title":"NK cell receptors and their ligands in leukemia","volume":"22","author":"Verheyden","year":"2007","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41409-021-01259-0","article-title":"Natural Killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: A study on behalf of the CTIWP of the EBMT","volume":"56","author":"Ruggeri","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2018.04.009","article-title":"NK cells mediate a crucial Graft-versus-Leukemia effect in haploidentical-HSCT to cure high-risk acute leukemia","volume":"39","author":"Locatelli","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1182\/blood-2002-08-2568","article-title":"Reconstitution of NK cell receptor repertoire followingHLA-matched hematopoietic cell transplantation","volume":"101","author":"Shilling","year":"2003","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2004-12-4825","article-title":"Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes","volume":"105","author":"Hsu","year":"2005","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2009-07-229740","article-title":"NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation","volume":"115","author":"Bjorklund","year":"2010","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bbmt.2006.04.008","article-title":"KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy","volume":"12","author":"Hsu","year":"2006","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.bbmt.2009.06.015","article-title":"Donor KIR3DL1\/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation","volume":"15","author":"Gagne","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1182\/blood-2009-08-236943","article-title":"Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation","volume":"115","author":"Venstrom","year":"2010","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.4049\/jimmunol.2100119","article-title":"Following transplantation for acute myelogenous leukemia, donor KIR Cen B02 better protects against relapse than KIR Cen B01","volume":"206","author":"Guethlein","year":"2021","journal-title":"J. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.bbmt.2009.11.022","article-title":"Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation","volume":"16","author":"Symons","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/ejh.12616","article-title":"Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation","volume":"96","author":"Anguita","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbmt.2017.11.042","article-title":"Killer cell immunoglobulin-like receptor-ligand mismatch in donor versus recipient direction provides better graft-versus-tumor effect in patients with hematologic malignancies undergoing allogeneic T cell-replete haploidentical transplantation followed by post-transplant cyclophosphamide","volume":"24","author":"Wanquet","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbmt.2018.01.013","article-title":"Selecting the best donor for haploidentical transplant: Impact of HLA, killer cell immunoglobulin-like receptor genotyping and other clinical variables","volume":"24","author":"Solomon","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.4049\/jimmunol.1801489","article-title":"Impact of KIR\/HLA incompatibilities on NK cell reconstitution and clinical outcome after T cell-replete haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide","volume":"202","author":"Willem","year":"2019","journal-title":"J. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-019-0251-3","article-title":"Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: A study of the Acute Leukemia Working Party of EBMT","volume":"9","author":"Shimoni","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-017-0498-8","article-title":"Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the EBMT","volume":"10","author":"Brissot","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Konuma, T., Yamasaki, S., Ishiyama, K., Mizuno, S., Hayashi, H., Uchida, N., Shimabukuro, M., Tanaka, M., Kuriyama, T., and Onizuka, M. (2024). Comparison of allogeneic transplant outcomes between matched sibling donors and alternative donors in patients over 50 years of age with acute myeloid leukemia: 8\/8 allele-matched unrelated donors and unrelated cord blood provide better leukemia-free survival compared with matched sibling donors during nonremission status. Transplant. Cell. Ther., 30.","DOI":"10.1016\/j.jtct.2023.12.002"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3324\/haematol.2017.187450","article-title":"Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: A report on 1578 patients from the Acute Leukemia Working Party of the EBMT","volume":"104","author":"Brissot","year":"2019","journal-title":"Haematologica"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00277-019-03593-2","article-title":"Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning\u2014A matched pair analysis","volume":"98","author":"Doppelhammer","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Mehta, R.S., Saliba, R.M., Ghanem, S., Alousi, A.M., Rondon, G., Anderlini, P., Al-Atrash, G., Bashir, Q., Hosing, C.M., and Im, J.S. (2022). Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transplant. Cell. Ther., 28.","DOI":"10.1016\/j.jtct.2022.04.020"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41409-025-02596-0","article-title":"Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"60","author":"Tarantino","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00262-008-0601-7","article-title":"Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells","volume":"58","author":"Verheyden","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00262-016-1806-9","article-title":"Killer-cell immunoglobulin-like receptor genes and ligands and their role in hematologic malignancies","volume":"65","author":"Varbanova","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1349-7006.2006.00356.x","article-title":"Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts","volume":"98","author":"Masuda","year":"2007","journal-title":"Cancer Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41375-021-01474-0","article-title":"Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia","volume":"36","author":"Shimomura","year":"2022","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.18530","article-title":"Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study","volume":"201","author":"Matsuda","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-019-0204-x","article-title":"Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: A report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT","volume":"9","author":"Baron","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7326\/0003-4819-120-8-199404150-00004","article-title":"Identical-twin bone marrow transplants for leukemia","volume":"120","author":"Gale","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.16185","article-title":"Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: A retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT","volume":"188","author":"Baron","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood.2025028617","article-title":"Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies","volume":"146","author":"Socie","year":"2025","journal-title":"Blood"},{"key":"ref_107","first-page":"1998","article-title":"Reduced incidence of relapse and graft-versus-host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation","volume":"110","author":"Kim","year":"2025","journal-title":"Haematologica"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: Basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT","volume":"105","author":"Dholaria","year":"2020","journal-title":"Haematologica"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"P1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): An open-label, multicentre, phsse 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood.2024025705","article-title":"How I treat AML relapse after allogeneic HSCT","volume":"145","author":"Gooptu","year":"2025","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Shin, D.Y. (2023). TP53 mutation in acute myeloid leukemia: An old foe revisited. Cancers, 15.","DOI":"10.3390\/cancers15194816"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jmcb\/mjz060","article-title":"P53 modifications: Exquisite decorations of the powerful guardian","volume":"11","author":"Liu","year":"2019","journal-title":"J. Mol. Cell Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/onc.2016.502","article-title":"Census and evaluation of p53 target genes","volume":"36","author":"Fischer","year":"2017","journal-title":"Oncogene"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.molmet.2019.10.002","article-title":"Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer","volume":"33","author":"Lacroix","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2024024245","article-title":"TP53-mutated acute myeloid leukemia: How can we improve outcomes?","volume":"145","author":"Sallman","year":"2025","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2013-12-544957","article-title":"Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"123","author":"Middeke","year":"2014","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bjh.13912","article-title":"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2016.07.018","article-title":"Clinical utility of next-generation sequencing for oncogenic mutations in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation","volume":"22","author":"Luskin","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: Impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-017-0393-3","article-title":"Allogeneic stem cell transplantation in adult patients with acute myeloid leukemia and 17p abnormalities in first complete remission: A study from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"10","author":"Labopin","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2018-99-116469","article-title":"Presence of TP53 mutation and monosomal karyotype predict the outcome of patients with acute myeloid leukemia in non-remission at allogeneic stem cell transplantation","volume":"132","author":"Najima","year":"2018","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/cncr.34268","article-title":"Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia","volume":"128","author":"Loke","year":"2022","journal-title":"Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","article-title":"TP53 mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation","volume":"9","author":"Lontos","year":"2025","journal-title":"Blood Adv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000526174","article-title":"The prognostic value of TP53 mutations in adult acute myeloid leukemia: A meta-analysis","volume":"50","author":"Qin","year":"2022","journal-title":"Transfus. Med. Hemotherapy"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Zhao, D., Zarif, M., Zhou, Q., Capo-Chichi, J.-M., Schuh, A., Minden, M.D., Atenafu, E.G., Kumar, R., and Chang, H. (2023). TP53 mutations in AML patients are associated with dismal clinical outcome irrespective of frontline induction regimen and allogeneic hematopoietic cell transplantation. Cancers, 15.","DOI":"10.3390\/cancers15123210"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","article-title":"Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML","volume":"8","author":"Nawas","year":"2024","journal-title":"Blood Adv."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","article-title":"Current status and new treatment approaches in TP53 mutated AML","volume":"32","author":"Hunter","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1080\/10428194.2022.2123228","article-title":"Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: A systematic review and meta-analysis","volume":"63","author":"Shahzad","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1002\/cam4.4661","article-title":"Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T-cells and regulatory T-cels in TP53-mutated acute myeloid leukemia","volume":"11","author":"Abolhalaj","year":"2022","journal-title":"Cancer Med."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Marvin-Peek, J., Mason, E.F., Kishtagari, A., Jayani, R.V., Dholaria, B., Kim, T.K., Engelhardt, B.G., Chen, H., Strickland, S., and Savani, B. (2023). TP53 mutations are associated with increased infections and reduced hematopoietic cell transplantation rates in myelodysplastic syndrome and acute myeloid leukemia. Transplant. Cell. Ther., 29.","DOI":"10.1016\/j.jtct.2023.03.008"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","article-title":"Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"37","author":"Badar","year":"2023","journal-title":"Leukemia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2021-154151","article-title":"Non-relapse mortality in TP53-mutated MDS\/AML\u2014A multi-center collaborative study","volume":"138","author":"Byrne","year":"2021","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.26941","article-title":"Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion","volume":"98","author":"Daver","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/ejh.14308","article-title":"Clonal evolution in 207 cases of refractory or relapsed acute myeloid leukemia","volume":"114","author":"Murray","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11899-011-0101-2","article-title":"Management of refractory acute myeloid leukemia: Re-induction therapy or straight to transplantation?","volume":"7","author":"Feldman","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:54:06Z","timestamp":1760090046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":146,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17203285"],"URL":"https:\/\/doi.org\/10.3390\/cancers17203285","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}